ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Relay Therapeutics Inc

Relay Therapeutics Inc (RLAY)

4.46
0.14
(3.24%)
Closed January 19 3:00PM
4.45
-0.01
(-0.22%)
After Hours: 5:03PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.45
Bid
4.26
Ask
4.58
Volume
3,391,675
4.11 Day's Range 4.59
3.50 52 Week Range 11.16
Market Cap
Previous Close
4.32
Open
4.28
Last Trade
5
@
4.54
Last Trade Time
Financial Volume
US$ 14,904,167
VWAP
4.3943
Average Volume (3m)
2,341,295
Shares Outstanding
167,382,958
Dividend Yield
-
PE Ratio
-2.18
Earnings Per Share (EPS)
-2.04
Revenue
31.97M
Net Profit
-341.97M

About Relay Therapeutics Inc

Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, i... Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Relay Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RLAY. The last closing price for Relay Therapeutics was US$4.32. Over the last year, Relay Therapeutics shares have traded in a share price range of US$ 3.50 to US$ 11.16.

Relay Therapeutics currently has 167,382,958 shares outstanding. The market capitalization of Relay Therapeutics is US$723.09 million. Relay Therapeutics has a price to earnings ratio (PE ratio) of -2.18.

RLAY Latest News

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.24-5.117270788914.695.993.553889924.35497345CS
40.214.952830188684.245.993.529267214.35387955CS
12-1.77-28.45659163996.226.483.523412954.75076951CS
26-4.06-47.70857814348.5110.723.520660846.2510821CS
52-6.15-58.018867924510.611.163.516646186.82341681CS
156-21.45-82.818532818525.935.363.5131498812.20455012CS
260-29.53-86.904061212533.9864.373.5106570716.66687107CS

RLAY - Frequently Asked Questions (FAQ)

What is the current Relay Therapeutics share price?
The current share price of Relay Therapeutics is US$ 4.45
How many Relay Therapeutics shares are in issue?
Relay Therapeutics has 167,382,958 shares in issue
What is the market cap of Relay Therapeutics?
The market capitalisation of Relay Therapeutics is USD 723.09M
What is the 1 year trading range for Relay Therapeutics share price?
Relay Therapeutics has traded in the range of US$ 3.50 to US$ 11.16 during the past year
What is the PE ratio of Relay Therapeutics?
The price to earnings ratio of Relay Therapeutics is -2.18
What is the cash to sales ratio of Relay Therapeutics?
The cash to sales ratio of Relay Therapeutics is 23.3
What is the reporting currency for Relay Therapeutics?
Relay Therapeutics reports financial results in USD
What is the latest annual turnover for Relay Therapeutics?
The latest annual turnover of Relay Therapeutics is USD 31.97M
What is the latest annual profit for Relay Therapeutics?
The latest annual profit of Relay Therapeutics is USD -341.97M
What is the registered address of Relay Therapeutics?
The registered address for Relay Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Relay Therapeutics website address?
The website address for Relay Therapeutics is www.relaytx.com
Which industry sector does Relay Therapeutics operate in?
Relay Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

RLAY Discussion

View Posts
georgie18 georgie18 6 days ago
RLAY...$4.89...HOD...🥳...Hit $5.99 on Friday...

georgie18

Member Level
Re: georgie18 post# 388314

Friday, January 10, 2025 1:35:14 PM

Post#
388363
of 388440
RLAY...$5.40...🥳...on the Breakout...off my $4.61 Alert...

georgie18

Member Level
Re: georgie18 post# 667618

Wednesday, January 08, 2025 5:37:01 PM

Post#
670914
of 671062
RLAY...$4.93...🥳...Off my $4.61 Alert...Bullish Psar flip..."W" Pattern in play here...Break/Hold $5.21 and we see $6.50/47 range...https://schrts.co/nAzyZemz

georgie18

Member Level
Re: georgie18 post# 386855

Thursday, December 12, 2024 9:51:02 AM

Post#
386875
of 388314
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...

georgie18

Member Level
Re: georgie18 post# 667203

Wednesday, December 11, 2024 2:48:21 PM

Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html

georgie18

Member Level
Re: RIGATONI post# 386680

Saturday, December 07, 2024 12:12:54 PM

Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
👍️0
georgie18 georgie18 1 week ago
RLAY...$5.40...🥳...on the Breakout...off my $4.61 Alert...

georgie18

Member Level
Re: georgie18 post# 667618

Wednesday, January 08, 2025 5:37:01 PM

Post#
670914
of 671062
RLAY...$4.93...🥳...Off my $4.61 Alert...Bullish Psar flip..."W" Pattern in play here...Break/Hold $5.21 and we see $6.50/47 range...https://schrts.co/nAzyZemz

georgie18

Member Level
Re: georgie18 post# 386855

Thursday, December 12, 2024 9:51:02 AM

Post#
386875
of 388314
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...

georgie18

Member Level
Re: georgie18 post# 667203

Wednesday, December 11, 2024 2:48:21 PM

Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html

georgie18

Member Level
Re: RIGATONI post# 386680

Saturday, December 07, 2024 12:12:54 PM

Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
👍️0
georgie18 georgie18 2 weeks ago
RLAY...$4.93...🥳...Off my $4.61 Alert...Bullish Psar flip..."W" Pattern in play here...Break/Hold $5.21 and we see $6.50/47 range...https://schrts.co/nAzyZemz

georgie18

Member Level
Re: georgie18 post# 386855

Thursday, December 12, 2024 9:51:02 AM

Post#
386875
of 388314
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...

georgie18

Member Level
Re: georgie18 post# 667203

Wednesday, December 11, 2024 2:48:21 PM

Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html

georgie18

Member Level
Re: RIGATONI post# 386680

Saturday, December 07, 2024 12:12:54 PM

Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
👍️0
Monksdream Monksdream 4 weeks ago
RLAY under $5

👍️0
georgie18 georgie18 1 month ago
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...

georgie18

Member Level
Re: georgie18 post# 667203

Wednesday, December 11, 2024 2:48:21 PM

Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html

georgie18

Member Level
Re: RIGATONI post# 386680

Saturday, December 07, 2024 12:12:54 PM

Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
👍️0
georgie18 georgie18 1 month ago
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html

georgie18

Member Level
Re: RIGATONI post# 386680

Saturday, December 07, 2024 12:12:54 PM

Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
👍️0
glenn1919 glenn1919 1 month ago
RLAY...................https://stockcharts.com/h-sc/ui?s=RLAY&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 1 month ago
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
👍️0
Monksdream Monksdream 3 months ago
RLAY under $10
👍️0
Monksdream Monksdream 10 months ago
RLAY under $10
👍️0
Monksdream Monksdream 2 years ago
Using AI to find the next blockbuster drug
This week, AI chipmaker Nvidia placed their bet — investing $50M into AI drug discovery platform Recursion Pharmaceuticals (NASDAQ:RXRX) — sending its stock up 78%.



Drugmakers are already benefiting from using AI to discover new drugs. And in the process, AI is speeding up and reducing the cost of the long and expensive drug development process.
Between 2015 and 2022, the cumulative investment in AI drug development has risen from under $1B to $24.6B.
In the next decade, Morgan Stanley expects AI will help develop an additional 50 drugs with an extra $50B in sales.
Following Nvidia’s investment, other AI drug discovery platforms rose on the news, including Exscientia (NASDAQ:EXAI), AbCellera Biologics (NASDAQ:ABCL) and Relay Therapeutics (NASDAQ:RLAY).
Recursion has five drugs, and Exscientia has three drugs discovered with AI, which are already in human trials. And within the startup sector, AI drug discovery has quickly become one of the hottest markets for investment.
👍️0

Your Recent History

Delayed Upgrade Clock